April 19, 2021

Jaguar Gene Therapy Closes $139 Million Series B Funding

On April 13th, 2021, Jaguar Gene Therapy announced it had secured $139 million in Series B funding, co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan.

Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases, including galactosemia, genetic causes of autism spectrum disorder, and Type 1 diabetes.

“We are thrilled to have attracted this prestigious group of visionary investors, which affirms our strategic approach, promising pipeline programs, and unique collaboration with Deerfield Management,” said Joe Nolan, Chief Executive Officer of Jaguar Gene Therapy. “With this capital infusion, we are well positioned to execute on our mission to accelerate breakthroughs in gene therapy and bring them to children and adults with severe genetic diseases.”

Axovia Therapeutics is a majority-owned subsidiary of Jaguar Gene Therapy. We are focused on creating transformative therapies for ciliopathies, advancing AXV101, a gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). A life-threatening neurometabolic condition, BBS causes progressive vision loss, severe obesity, learning disorders and kidney disease.

We are excited to see continued traction in the field of gene therapy and eagerly anticipate the advancements Jaguar will make to help those suffering from genetic diseases.